Immunohistochemistry and Western blotting have shown that low levels of TSPAN9 expression were detected in clinical tumor specimens and gastric cancer cell lines, but elevated TSPAN9 expression was associated with poor prognosis, which encouraged us to conduct more in-depth research on TSPAN9. This evidence concerns the gene TSPAN9 and neoplasm.